BUSINESSQUARTZ
Moderna beat earnings expectations but its norovirus vaccine trial hit a wall
Moderna exceeded Wall Street's loss estimates, but its norovirus vaccine trial failed to meet a key objective, leading to a decline in its stock price.
Related Signal
Adjacent reporting
- Moderna CEO on Earnings, Flu Shots and Skin Cancer Trials
- Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
- Here’s how much Moderna’s stock has rallied off renewed focus on hantavirus research
- Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
- AbbVie beat profit estimates but cut its forecast — and the stock sank
- Novo Nordisk shares dive after heart medicine fails trial